Literature DB >> 21652600

Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses.

Lamiae Grimaldi-Bensouda1, Annick Alpérovitch, Gérard Besson, Christophe Vial, Jean-Marie Cuisset, Caroline Papeix, Olivier Lyon-Caen, Jacques Benichou, Michel Rossignol.   

Abstract

The role of influenzalike illnesses and influenza vaccination in the development of Guillain-Barré syndrome (GBS), particularly the role of A/H1N1 epidemics and A/H1N1 vaccination, is debated. Data on all incident GBS cases meeting the Brighton Collaboration criteria that were diagnosed at 25 neurology centers in France were prospectively collected between March 2007 and June 2010, covering 3 influenzavirus seasons, including the 2009-2010 A/H1N1 outbreak. A total of 457 general practitioners provided a registry of patients from which 1,080 controls were matched by age, gender, index date (calendar month), and region to 145 cases. Causal relations were assessed by multivariate case-control analysis with adjustment for risk factors (personal and family history of autoimmune disorders, among others), while matching on age, gender, and calendar time. Influenza (seasonal or A/H1N1) or influenzalike symptoms in the 2 months preceding the index date was associated with GBS, with a matched odds ratio of 2.3 (95% confidence interval (CI): 0.7, 8.2). The difference in the rates of GBS occurring between influenza virus circulation periods and noncirculation periods was highly statistically significant (P = 0.004). Adjusted odds ratios for GBS occurrence within 6 weeks after seasonal and A/H1N1 vaccination were 1.3 (95% CI: 0.4, 4.1) and 0.9 (95% CI: 0.1, 7.6), respectively. Study results confirm that influenza virus is a likely risk factor for GBS. Conversely, no new concerns have arisen regarding influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652600     DOI: 10.1093/aje/kwr072

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  21 in total

1.  Pharmacoepidemiology.

Authors:  Stephen J W Evans
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.

Authors:  Sharon K Greene; Melisa Rett; Eric S Weintraub; Lingling Li; Ruihua Yin; Anthony A Amato; Doreen T Ho; Sarah I Sheikh; Bruce H Fireman; Matthew F Daley; Edward A Belongia; Steven J Jacobsen; Roger Baxter; Tracy A Lieu; Martin Kulldorff; Claudia Vellozzi; Grace M Lee
Journal:  Am J Epidemiol       Date:  2012-05-11       Impact factor: 4.897

3.  Cumulative risk of Guillain-Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic.

Authors:  Claudia Vellozzi; Shahed Iqbal; Brock Stewart; Jerome Tokars; Frank DeStefano
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

4.  Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.

Authors:  Hélène Théophile; Nicholas Moore; Philip Robinson; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

5.  A 3-month-old baby with H1N1 and Guillain-Barré syndrome.

Authors:  Alexandra Vasconcelos; Francisco Abecasis; Rita Monteiro; Cristina Camilo; Marisa Vieira; Mamede de Carvalho; Manuela Correia
Journal:  BMJ Case Rep       Date:  2012-03-27

6.  STATEMENT ON SEASONAL INFLUENZA VACCINE FOR 2012-2013: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2012-08-01

7.  Statement on Seasonal Influenza Vaccine for 2013-2014: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2013-10-10

8.  COVID-19-Associated Bifacial Weakness with Paresthesia Subtype of Guillain-Barré Syndrome.

Authors:  K L Hutchins; J H Jansen; A D Comer; R V Scheer; G S Zahn; A E Capps; L M Weaver; N A Koontz
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-25       Impact factor: 3.825

Review 9.  [Guillain-Barré syndrome after exposure to influenza].

Authors:  H-P Hartung; B Keller-Stanislawski; R A Hughes; H C Lehmann
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

10.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study.

Authors:  Van-Mai Cao-Lormeau; Alexandre Blake; Sandrine Mons; Stéphane Lastère; Claudine Roche; Jessica Vanhomwegen; Timothée Dub; Laure Baudouin; Anita Teissier; Philippe Larre; Anne-Laure Vial; Christophe Decam; Valérie Choumet; Susan K Halstead; Hugh J Willison; Lucile Musset; Jean-Claude Manuguerra; Philippe Despres; Emmanuel Fournier; Henri-Pierre Mallet; Didier Musso; Arnaud Fontanet; Jean Neil; Frédéric Ghawché
Journal:  Lancet       Date:  2016-03-02       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.